Mercaptopurine-induced hepatoportal sclerosis in a patient with Crohn's disease
| Autor: | Thomas D. Schiano, Maria Isabel Fiel, Mark Krakauer, Mohamed Alzaabi, Peter Legnani, Ana C. Tuyama |
|---|---|
| Rok vydání: | 2013 |
| Předmět: |
Male
medicine.medical_specialty Hepatoportal sclerosis Azathioprine Gastroenterology Inflammatory bowel disease Young Adult Crohn Disease Liver Function Tests Internal medicine Hypertension Portal Humans Medicine Hepatitis Crohn's disease Sclerosis medicine.diagnostic_test Mercaptopurine business.industry Ascites General Medicine medicine.disease Portal System business Liver function tests Immunosuppressive Agents Intestinal Obstruction Nodular regenerative hyperplasia medicine.drug |
| Zdroj: | Journal of Crohn's and Colitis. 7:590-593 |
| ISSN: | 1873-9946 |
| DOI: | 10.1016/j.crohns.2012.07.006 |
| Popis: | Thiopurines play a pivotal role in the management of inflammatory bowel disease. Azathioprine and mercaptopurine have been associated with a number of liver abnormalities, including hepatitis, veno-occlusive disease, nodular regenerative hyperplasia, and peliosis hepatitis. Patients treated with azathioprine and mercaptopurine have their liver chemistry tests routinely checked due to this potential for hepatotoxicity. Hepatoportal sclerosis is a cause of non-cirrhotic portal hypertension that is increasingly being recognized; its etiopathogenesis is not well defined. We present the first case report of mercaptopurine-induced hepatoportal sclerosis leading to non-cirrhotic portal hypertension in a patient with Crohn's disease. He had been treated with mercaptopurine for five years, and his liver chemistry tests were always within normal limits. This case underscores the potential serious liver adverse events that may arise silently and go undetected during treatment with mercaptopurine, and should alert clinicians as to the potential need to discontinue mercaptopurine in this setting. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|